NJ001识别抗原在多种肿瘤组织中的表达及其与肿瘤分化的关系

目的:研究NJ001识别抗原在人体内多种恶性肿瘤组织中的表达情况,并评估其与肿瘤分化的关系?方法:采用免疫组化的方法对肺腺癌?肺鳞癌?胰腺癌?乳腺癌?食管癌?胃癌?肝癌和对应的良性病变组织中NJ001识别抗原的表达进行检测,同时与肿瘤分化程度进行比较,通过半定量的方法判定结果,使用χ2检验或Fisher确切概率法进行相关性分析?结果:NJ001识别抗原在肺腺癌(88.0%)?肺鳞癌(82.2%)?胰腺癌(73.3%)和乳腺癌(57.8%)中均呈现出高表达,并且均与肿瘤分化程度显著相关(肺腺癌P < 0.001,肺鳞癌P=0.002,胰腺癌P=0.002,乳腺癌P=0.024)?结论:NJ001识别抗原有望为临床诊断肺腺癌?肺鳞癌?胰腺癌和乳腺癌及判断其分化程度提供一个新的肿瘤标志物?

Expression of NJ001 recognized antigen and its association with tumor differentiation in multiple neoplasms

Objective:To examine NJ001 recognized antigen expression in surgically resected human malignant tumor tissues,and to evaluate the relationship between its expression and tumor differentiation. Methods:NJ001 recognized antigen expression was immunohistochemically studied in lung adenocarcinoma,lung squamous carcinoma,pancreatic cancer,breast cancer,esophageal cancer,gastric cancer,liver cancer and matched non-neoplastic tissues,and all positive cases were compared on tumor differentiation. The results were scored by semiquantitative analysis,and statistical analysis was evaluated by chi-square test or Fisher exact test. Results:Expression of NJ001 recognized antigen was significantly high in lung adenocarcinoma (88.0%),lung squamous carcinoma(82.2%),pancreatic cancer(73.3%)and breast cancer(57.8%),and was significantly correlated with lower differentiation degree in all these tumors (P < 0.001 in lung adenocarcinoma;P=0.002 in lung squamous carcinoma;P=0.002 in pancreatic cancer;and P=0.024 in breast cancer). Conclusion:NJ001 recognized antigen is expected to be a tumor marker in lung adenocarcinoma,lung squamous carcinoma,breast cancer and pancreatic cancer,as well as a remarkable biomarker for identification of differentiation degree in multiple neoplasms.